PA
NAGE

Parallel Advisors’s Niagen Bioscience NAGE Stock Holding History

Parallel Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160 Buy
+50
New +$203 ﹤0.01% 3860
2021
Q3 		– Sell
-100
Closed -$1K – 3303
2021
Q2 		$1K Buy
+100
New +$872 ﹤0.01% 2863

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Parallel Advisors's NAGE Position: Q2 2026 in Review

Parallel Advisors opened a new position in Niagen Bioscience (NAGE) in Q2 2026: 50 shares worth $160. The stake represents ﹤0.01% of the portfolio and ranks #3860 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in NAGE as recently as Q2 2021.

Parallel Advisors first reported a position in NAGE in Q2 2021 and has held it in 2 quarters since. The position peaked at $1K in Q2 2021. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Parallel Advisors held 50 shares of Niagen Bioscience worth $160 as of Q2 2026.
  • Niagen Bioscience was a new Parallel Advisors position in Q2 2026.
  • Niagen Bioscience made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3860 holding.
  • Parallel Advisors first reported a position in Niagen Bioscience in Q2 2021 and has held it in 2 quarters since.
  • Parallel Advisors's Niagen Bioscience position peaked at $1K in Q2 2021.
  • 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.